Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
$1.43
$0.51
$77.77
$30.72M1.681.37 million shs941,400 shs
OS Therapies Inc stock logo
OSTX
OS Therapies
$2.48
+3.3%
$1.83
$1.12
$7.00
$79.09MN/A737,634 shs1.08 million shs
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
$4.95
+0.2%
$4.83
$0.13
$1.04
$95.30M1.581.05 million shs6,032 shs
WHWK
Whitehawk Therapeutics
$1.74
+5.5%
$1.83
$1.39
$3.81
$82M0.55100,515 shs70,989 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
0.00%0.00%0.00%0.00%0.00%
OS Therapies Inc stock logo
OSTX
OS Therapies
0.00%+20.39%+43.35%+47.62%-38.00%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
+0.17%+0.37%+2.66%-5.56%+2,091.50%
WHWK
Whitehawk Therapeutics
0.00%+8.75%-10.31%+173,999,900.00%+173,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
N/AN/AN/AN/AN/AN/AN/AN/A
OS Therapies Inc stock logo
OSTX
OS Therapies
2.3788 of 5 stars
3.60.00.00.02.80.80.6
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
WHWK
Whitehawk Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
0.00
N/AN/AN/A
OS Therapies Inc stock logo
OSTX
OS Therapies
3.25
Buy$18.00625.81% Upside
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
2.00
Hold$5.001.04% Upside
WHWK
Whitehawk Therapeutics
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest ORPH, VIRI, WHWK, and OSTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/20/2025
OS Therapies Inc stock logo
OSTX
OS Therapies
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
8/11/2025
WHWK
Whitehawk Therapeutics
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell
8/7/2025
OS Therapies Inc stock logo
OSTX
OS Therapies
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
7/14/2025
OS Therapies Inc stock logo
OSTX
OS Therapies
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
6/30/2025
OS Therapies Inc stock logo
OSTX
OS Therapies
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
6/24/2025
OS Therapies Inc stock logo
OSTX
OS Therapies
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
6/9/2025
OS Therapies Inc stock logo
OSTX
OS Therapies
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
N/AN/AN/AN/A$2.74 per shareN/A
OS Therapies Inc stock logo
OSTX
OS Therapies
N/AN/AN/AN/AN/AN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/A$0.20 per shareN/A
WHWK
Whitehawk Therapeutics
$25.98M3.16N/AN/A$2.12 per share0.82
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
-$97.01MN/A0.00N/AN/AN/AN/AN/AN/A
OS Therapies Inc stock logo
OSTX
OS Therapies
-$7.79M-$0.79N/AN/AN/AN/AN/A-569.57%N/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
-$5.30M-$0.27N/AN/AN/AN/A-130.33%-115.00%N/A
WHWK
Whitehawk Therapeutics
-$63.69M-$0.060.00N/A99.42%-75.99%-68.57%N/A

Latest ORPH, VIRI, WHWK, and OSTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
WHWK
Whitehawk Therapeutics
$0.49-$0.76-$1.25-$0.76$100.00 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
N/AN/AN/AN/AN/A
OS Therapies Inc stock logo
OSTX
OS Therapies
N/AN/AN/AN/AN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/AN/A
WHWK
Whitehawk Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
0.14
1.80
N/A
OS Therapies Inc stock logo
OSTX
OS Therapies
N/A
0.76
0.76
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/A
7.27
7.27
WHWK
Whitehawk Therapeutics
N/A
20.41
20.41

Institutional Ownership

CompanyInstitutional Ownership
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
10.74%
OS Therapies Inc stock logo
OSTX
OS Therapies
N/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
9.05%
WHWK
Whitehawk Therapeutics
52.08%

Insider Ownership

CompanyInsider Ownership
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
N/A
OS Therapies Inc stock logo
OSTX
OS Therapies
13.80%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
12.20%
WHWK
Whitehawk Therapeutics
49.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
14135.31 millionN/ANot Optionable
OS Therapies Inc stock logo
OSTX
OS Therapies
N/A31.89 millionN/AN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
519.26 million16.91 millionOptionable
WHWK
Whitehawk Therapeutics
4047.13 million23.61 millionN/A

New MarketBeat Followers Over Time

Media Sentiment Over Time

Orphazyme A/S stock logo

Orphazyme A/S NASDAQ:ORPH

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

OS Therapies stock logo

OS Therapies NYSE:OSTX

$2.48 +0.08 (+3.33%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$2.43 -0.05 (-2.18%)
As of 08/22/2025 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

Virios Therapeutics stock logo

Virios Therapeutics NASDAQ:VIRI

$4.95 +0.01 (+0.17%)
As of 08/22/2025

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

Whitehawk Therapeutics NASDAQ:WHWK

$1.74 +0.09 (+5.45%)
As of 08/22/2025 04:00 PM Eastern

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.